New EULAR guidelines speed RA treatment switches as rheumatoid arthritis biosimilars and biosimilar cost savings push earlier ...

Early diagnosis leads to earlier treatment. With earlier treatment of rheumatoid arthritis (RA), there is a better chance for less radiographic damage, less disability and thus lower overall costs of ...

1 in 100 people in Britain today live with rheumatoid arthritis (RA). Unlike osteoarthritis (OA), RA is caused not by wear and tear but by the body's immune system attacking its own joints. RA can ...

Management of rheumatoid arthritis (RA) has evolved from simply the direct translation of drug efficacy results from clinical trials to patient care, to a more complex longitudinal process that ...

Rheumatoid arthritis-associated interstitial lung disease (ILD) presents a paradox: it is common and a major cause of ...

The treat-to-target (T2T) strategy, which involves predefined therapy objectives and a focused monitoring system, has substantially improved the management of rheumatoid arthritis (RA). These benefits ...

First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease, have been relied upon by healthcare professionals and organizations ...